Register Now for NAAF's 39th Annual Patient Conference June 27-30, 2024 in Washington, D.C.!

Clinical Trials & Research Studies

Clinical research uses human volunteers to add to medical knowledge. Clinical research includes trials that test new treatments and therapies, genetic studies to explore ways in which a person’s genes may contribute to developing a disorder and epidemiological studies to understand the patterns, causes, and effects of health and disease.

Clinical Trials

Human clinical trials are a critical phase to bringing safe and effective treatments to market. Many tests are conducted before the clinical trial stage to determine whether potential treatments are appropriate for testing in people. It is through clinical trials that safe and effective drugs, therapies and potentially, a cure for alopecia areata will be discovered.

By participating in a clinical trial, you play an important role in the effort to develop effective treatments for alopecia areata. The decision to participate is very personal and should be made only after speaking with your health care provider and other individuals you trust. You can stop participation in a clinical trial at any time if new concerns arise or you lose confidence that its potential benefits outweigh its risks.

Clinical Trial Resources

ClinicalTrials.gov is a resource from the U.S. National Library of Medicine that offers up-to-date information for locating federally and privately supported clinical trials for a wide range of diseases and conditions. Visit ClinicalTrials.gov to review clinical trials that are recruiting particpants for studies on alopecia areata and other diseases.

Watch a webinar to learn more about clinical trials and how to search on ClinicalTrials.gov.

Download our guide to using ClinicalTrials.gov.

Download our worksheet, Clinical Trials and You, with questions to ask your doctor.

 

NAAF Postings for Clinical Trials and Research Studies

The National Alopecia Areata Foundation is committed to delivering accurate and reliable information to everyone affected by alopecia areata, and subsequently reviews many requests for postings about participation in research studies. The following is a current list of clinical trials and research studies working with NAAF  to recruit people with alopecia areata for particpation.

Disclaimer: NAAF provides research notices as an informational service to its community. NAAF is not conducting the study. This information does not represent a NAAF endorsement, but rather makes you aware that clinical studies are available for your participation if you choose. If you are presently under the care of a physician for alopecia areata, or other conditions, you should discuss clinical trial particpation  with your doctor before altering your treatment program. NAAF is not responsible for any adverse outcomes.

#Clinical Trials

A Study to Evaluate the Safety of an Investigational Topical JAK Inhibitor Suspension in Adults with Alopecia Areata

Learn More
Study type: Clinical Trials Posting date: 05/22/2023 Last updated: 05/20/2024 Status: Recruiting Phase: Phase 1 Country: United States Eligibility:

18 to 70 years of age; patchy AA with 30% to 80% scalp hair loss

Drug: Investigational topical JAK inhibitor suspension Administration: Topical Sponsor: Arcutis Biotherapeutics Sponsor Link: Click here
#Clinical Trials

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS)

Learn More
Study type: Clinical Trials Posting date: 06/20/2023 Last updated: 06/20/2023 Status: Recruiting Phase: Phase 3 Country: United States Eligibility:

6 years to 17 years at the age of consent (enrollment will be fully sequential by age group, with adolescents (12 to less than 18 years old) enrolling before children (6 to less than 12 years old)

Drug: Baricitinib (LY3009104) or placebo Administration: Oral Sponsor: Eli Lilly Pharmaceuticals Sponsor Link: Click here ClinicalTrials.gov: Click here
#Clinical Trials

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult Participants With Severe Alopecia Areata (Up-AA)

Learn More
Study type: Clinical Trials Posting date: 05/21/2024 Last updated: 05/21/2024 Status: Recruiting Phase: Phase 3 Country: United States Eligibility:

Age 18 to < 64; diagnosis of severe AA; 50% or greater scalp hair loss; experienceing current episode of AA for less than 8 years

Drug: upadacitinib Administration: Oral Sponsor: AbbVie Sponsor Link: Click here ClinicalTrials.gov: Click here
#Clinical Trials

Dupilumab in the Treatment of Pediatric Alopecia Areata (PEDAL)

Learn More
Study type: Clinical Trials Posting date: 05/21/2024 Last updated: 05/21/2024 Status: Recruiting Phase: Phase 2 Country: United States Eligibility:

Ages 6 to under 18 years old; history of at least 6 months with moderate to severe AA (≥ 30% scalp hair loss) screening IgE ≥ 200 and/or personal and/or familial history of atopy (including asthma, atopic dermatitis, allergic rhinitis, food allergy, or eosinophilic esophagitis)

Drug: Dupilumab Administration: subcutaneous injection Sponsor: Icahn School of Medicine at Mount Sinai ClinicalTrials.gov: Click here
#Clinical Trials

Dupilumab in the Treatment of Alopecia Areata Patients With an Atopic Background and/or High IgE

Learn More
Study type: Clinical Trials Posting date: 05/21/2024 Last updated: 05/21/2024 Status: Recruiting Phase: Phase 2 Country: United States Eligibility:

Age 18 years or older; history of at least 6 months of moderate to severe AA (≥ 50% scalp involvement); screening IgE > 200 and/or personal and/or familial history of atopy

Drug: Dupilumab Administration: subcutaneous injection Sponsor: Icahn School of Medicine at Mount Sinai ClinicalTrials.gov: Click here
#Clinical Trials

Phase 2a Study to Investigate Farudodstat in Adults with Alopecia Areata

Learn More
Study type: Clinical Trials Posting date: 05/22/2023 Last updated: 12/13/2023 Status: Recruiting Phase: Phase 2a Country: United States Eligibility:

18 years of age or older; diagnosed with alopecia areata; have at least 30% scalp hair loss

Drug: Farudodstat Administration: Oral Sponsor: ASLAN Pharmaceuticals Sponsor Link: Click here ClinicalTrials.gov: Click here
#Clinical Trials

Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

Learn More
Study type: Clinical Trials Posting date: 05/22/2024 Last updated: 05/22/2024 Status: Recruiting Phase: Phase 2 Country: United States Eligibility:

Age at least 18 years ≤60 years for males or ≤70 years of age for females; diagnosis of  severe to very severe AA with ≥ 50% scalp hair loss; current episode of severe to very severe AA of less than 8 years

Drug: Rezpegaldesleukin Administration: Sponsor: Nektar Therapeutics ClinicalTrials.gov: Click here
#Research Studies

Natural History and Pathogenesis of Alopecia in Children and Adults

Learn More
Study type: Research Studies Posting date: 05/22/2024 Last updated: 05/22/2024 Status: Recruiting Country: United States Eligibility:

Age 2 and up; diagnosis of immune-mediated alopecia

Drug: Administration: Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ClinicalTrials.gov: Click here
#Research Studies

Alopecia Areata and Vascular Health

Learn More
Study type: Research Studies Posting date: 10/31/2023 Last updated: 10/31/2023 Status: Recruiting Country: United States Eligibility:

18 years or older; diagnosed with alopecia areata; no history of heart attack or stroke

Drug: not applicable Administration: not applicable Sponsor: NYU Langone Health
#Clinical Trials

Randomized, Double-Blind, Placebo-Controlled Phase 2a, Proof-of-Concept Trial of ADX-914 for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

Learn More
Study type: Clinical Trials Posting date: 10/23/2023 Last updated: 05/21/2024 Status: Active/Fully Enrolled Phase: Phase 2a Country: United States Eligibility:

18 years to 75 years of age; diagnosed with alopecia areata

Drug: ADX-914 Administration: subcutaneous injection Sponsor: Q32 Bio Sponsor Link: Click here ClinicalTrials.gov: Click here